Moderna said late Thursday that it asked the Food and Drug Administration for emergency authorization of a second booster of its coronavirus vaccine for all adults, a significantly broader request than Pfizer and BioNTech filed for their shot this week.

The request is likely to intensify the latest round of an ongoing scientific debate over how long protection from the two most-used vaccines in the United States lasts in the face of new variants.